Revolution Medicines, Inc. RVMD

Company Overview

Revolution Medicines, Inc. (NASDAQ: RVMD) is a clinical-stage precision oncology company focused on developing targeted therapies for cancers driven by mutations in the RAS signaling pathway. The company operates within the biotechnology and oncology therapeutics industries and concentrates on discovering and commercializing small-molecule medicines designed to inhibit cancer-driving proteins that have historically been difficult to target. Its research and development strategy is centered on RAS-addicted cancers, including tumors involving KRAS, NRAS, and related signaling mechanisms.

The company’s primary value drivers are its oncology pipeline candidates, particularly RAS(ON) inhibitors targeting KRAS G12C and other RAS variants. Key development programs include compounds such as RMC-6236 and RMC-6291, along with additional investigational therapies aimed at pan-RAS inhibition and combination treatment approaches. Revolution Medicines was founded in 2014 and evolved from a discovery-stage biotechnology platform into a late-stage clinical oncology company through partnerships, capital markets financing, and expanded internal drug development capabilities. The company has positioned itself within a competitive segment of oncology focused on precision medicines for genetically defined cancers.